Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomised phase III intergroup study initiated by the AIO and AGMT (ML18147)

被引：0
|
作者：
Greil, R. [1 ]
Arnold, D. [2 ]
Hegewisch-Becker, S.
Freier, W.
Steffens, C. -C. [3 ]
Bertram, M.
Schlichting, C. [4 ]
Andel, J. [5 ]
Taylor, M. [6 ]
Makrutzki, M. [7 ]
Kubicka, S. [8 ]
机构：
[1] Paracelsus Med Univ, Salzburg, Austria
[2] UCCH, Hubertus Wald Tumor Ctr, Hamburg, Germany
[3] MVZ Haematol Onkol Klin Dr Hancken, Stade, Germany
[4] Diakoniekrankenhaus gGmbH, Rotenburg, Germany
[5] LKH Steyr, Steyr, Austria
[6] Genentech Inc, Epidemiol Patient Reported Outcomes & Healthcare, San Francisco, CA 94080 USA
[7] F Hoffmann La Roche & Cie AG, Basel, Switzerland
[8] Kleiskliniken Reutlingen GmbH, Med Klin 1, Reutlingen, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：254 / 254
页数：1
相关论文
共 50 条
  • [41] Bevacizumab plus chemotherapy as first-line therapy for elderly patients with metastatic colorectal cancer: Interim results of the noninterventional CASSIOPEE study.
    Francois, Eric
    Kim, Stefano Chong Hun
    Burki, Franck
    Laplaige, Philippe
    Smith, Denis Michel
    Gourgou, Sophie
    Rollot, Florence
    Barue, Vanessa
    Gandon, Sophie
    Mineur, Laurent
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Second-line bevacizumab plus FOLFOX in patients with metastatic colorectal cancer previously treated with adjuvant oxaliplatin-based chemotherapy.
    Chun, Sang Hoon
    Kim, Jung Hoon
    Kwag, Seung-Jin
    Kang, Myoung Hee
    Park, Ji-Ho
    Lee, Gyeong-Won
    Kang, Jung Hun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 157 - 157
  • [43] Efficacy and safety of surgery with curative intent in patients treated with first-line Bevacizumab plus chemotherapy for metastatic colorectal cancer: First beat
    Kretzschmar, A.
    Cunningham, D.
    Berry, S.
    Rivera, F.
    Di Bartolomeo, M.
    Mazier, M.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2008, 19 : I25 - I25
  • [44] Bevacizumab plus chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results
    Aparicio, T.
    Bouche, O.
    Taieb, J.
    Maillard, E.
    Kirscher, S.
    Etienne, P. -L.
    Faroux, R.
    Akouz, F. Khemissa
    El Hajbi, F.
    Locher, C.
    Rinaldi, Y.
    Lecomte, T.
    Lavau-Denes, S.
    Baconnier, M.
    Oden-Gangloff, A.
    Genet, D.
    Paillaud, E.
    Retornaz, F.
    Francois, E.
    Bedenne, L.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 133 - 138
  • [45] First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
    Diaz-Rubio, Eduardo
    Gomez-Espana, Auxiliadora
    Massuti, Bartomeu
    Sastre, Javier
    Abad, Albert
    Valladares, Manuel
    Rivera, Fernando
    Safont, Maria J.
    Martinez de Prado, Purificacion
    Gallen, Manuel
    Gonzalez, Encarnacion
    Marcuello, Eugenio
    Benavides, Manuel
    Fernandez-Martos, Carlos
    Losa, Ferran
    Escudero, Pilar
    Arrivi, Antonio
    Cervantes, Andres
    Duenas, Rosario
    Lopez-Ladron, Amelia
    Lacasta, Adelaida
    Llanos, Marta
    Tabernero, Jose M.
    Anton, Antonio
    Aranda, Enrique
    ONCOLOGIST, 2012, 17 (01): : 15 - 25
  • [46] FOLFIRI plus bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9-FFCD 0802)
    Aparicio, Thomas
    Linot, Benjamin
    Le Malicot, Karine
    Bouche, Olivier
    Boige, Valerie
    Francois, Eric
    Ghiringhelli, Francois
    Legoux, Jean-Louis
    Ben Abdelghani, Meher
    Phelip, Jean-Marc
    Faroux, Roger
    Dahan, Laetitia
    Taieb, Julien
    Bedenne, Laurent
    DIGESTIVE AND LIVER DISEASE, 2015, 47 (04) : 271 - 272
  • [47] Bevacizumab in patients with previously treated metastatic colorectal cancer: preliminary results of a phase II study (bevacolor)
    Borg, C.
    Delord, J. P.
    Husseini, F.
    Lenoir, V. Trillet
    Faroux, R.
    Francois, E.
    Ychou, M.
    Bergougnoux, L.
    Bennouna, J.
    Douillard, J. Y.
    EJC SUPPLEMENTS, 2007, 5 (04): : 257 - 257
  • [48] Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
    Mooi, Jennifer
    Chionh, Fiona
    Savas, Peter
    Duarte, Jessica Da Gama
    Chong, Geoffrey
    Brown, Stephen
    Wong, Rachel
    Price, Timothy J.
    Wann, Alysson
    Skrinos, Effie
    Mariadason, John M.
    Tebbutt, Niall C.
    CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2159 - 2167
  • [49] Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (MCRC) treated with bevacizumab (BV) plus chemotherapy (CT)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Purdie, D.
    Yi, J.
    Sugrue, M.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [50] Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
    Yang, Qiong
    Yin, Chenxi
    Liao, Fangxin
    Huang, Yuanyuan
    He, Wenzhuo
    Jiang, Chang
    Guo, Guifang
    Zhang, Bei
    Xia, Liangping
    ONCOTARGETS AND THERAPY, 2015, 8 : 2407 - 2413
12345